Yi-Bin Chen, MD

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.

Drs Yi-Bin Chen and Sophie Paczesny highlight data from key investigational approaches presented at recent meetings.

Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.

Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, detail novel strategies under investigation for the treatment of acute GVHD.

Experts discuss the current options for treating acute GVHD, including the use of corticosteroids and their management.

Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.

Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.

Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.

Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.

Yi-Bin Chen, MD, discusses key data on the use of vedolizumab in lower gastrointestinal acute Graft-Versus-Host Disease according to the phase 3 GRAPHITE study.

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.

Shifting their focus to acute graft versus host disease, panelists reflect on evolving treatment strategies and novel therapeutics.

Expert panelists share their perspectives on ongoing treatment evolutions in the setting of chronic graft versus host disease.

Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.

Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.

An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.

Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.